On Jan 12, 2019 Xoma Corporation (NASDAQ:XOMA) Shorts Rose By 7.15%

XOMA Corporation (NASDAQ:XOMA) Corporate Logo

Xoma Corporation (NASDAQ:XOMA) noted an increase of 7.15% in shorted shares. FINRA announced in January XOMA’s total 1.03M shorted shares. The 965,400 previous shares are up with 7.15%. Former XOMA’s position will need 7 days to recover. It has 144,000 average volume. Xoma Corporation float short is 16.45%.

The stock decreased 2.78% or $0.4 during the last trading session, hitting $14.Currently XOMA Corporation is downtrending after 55.68% change in last January 12, 2018. XOMA has also 60,602 shares volume. XOMA underperformed by 55.68% the S&P500.

XOMA Corporation discovers, develops, and commercializes antibody therapeutics in the United States, Europe, and the Asia Pacific.The company has $121.53 million market cap. The company??s product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia.Currently it has negative earnings. The Company’s preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy.

For more XOMA Corporation (NASDAQ:XOMA) news posted recently go to: Benzinga.com, Nasdaq.com, Streetinsider.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “Daily Biotech Pulse: Clinical Hold Lifted Off Crispr’s Gene-Edited Therapy, Endra To Offer Shares – Benzinga” posted on October 11, 2018, “4 Biotech Stocks to Watch in the New Year – Nasdaq” on January 05, 2018, “XOMA (XOMA) says Novartis has not communicated contents of CRL nor its plans going forward with respect to canakinumab – StreetInsider.com” with a publish date: October 18, 2018, “XOMA Acquires Royalty Interest Position from Agenus on Seven Assets Being Developed by Merck and Incyte – GlobeNewswire” and the last “XOMA Strengthens Leadership Team with Appointments of Chief Business Officer and General Counsel – GlobeNewswire” with publication date: January 08, 2018.

XOMA Corporation (NASDAQ:XOMA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.